--News Direct--
Radiopharm Theranostics Ltd (ASX:RAD) CEO and managing director Riccardo Canevari tells Proactive the company has begun the initiation process for entry into the Nasdaq stock exchange under the ticker RADX, gaining a second listing in the US capital market. RAD’s recently announced that it has received US FDA Investigational New Drug Application (IND) approval for its αVβ6 Integrin (RAD301) technology. With this approval the company can start a Phase 1 imaging trial in ambulatory patients with pancreatic cancer.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/radiopharm-theranostics-talks-clinical-development-and-nasdaq-listing-330445820
